Welcome to our dedicated page for SANGAMO THERAPEUTICS SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sangamo Therapeutics filings document regulatory, clinical, financial and corporate-status disclosures for a genomic medicine company developing gene therapy and genome-engineering technologies. Recent 8-K reports cover operating and financial results, clinical data from the STAAR study of isaralgagene civaparvovec, or ST-920, regulatory-pathway disclosures for Fabry disease, and material-event updates tied to the company's neurology pipeline.
The filing record also includes Nasdaq listing-compliance and delisting notices, SGMO common-stock registration information, finance leadership and officer-transition disclosures, and capital-structure information. These documents formalize the company's reported results, governance changes, securities status and clinical-regulatory events under SEC reporting rules.
Sangamo Therapeutics is offering 35,190,292 shares of common stock, pre-funded warrants for 17,787,033 shares, and purchase warrants for 52,977,325 shares. Securities are priced at $0.4719 per share and accompanying purchase warrant (or $0.4619 for a pre-funded warrant plus purchase warrant), yielding gross proceeds of about $24.8 million and estimated net proceeds of about $22.9 million before any warrant exercises.
The company plans to use the cash for working capital and general corporate purposes. Sangamo estimates cash and cash equivalents of approximately $20.9 million as of December 31, 2025 and, together with $2.0 million from its at-the-market program and this offering, expects funding only into the beginning of the third quarter of 2026.
The filing states there is substantial doubt about Sangamo’s ability to continue as a going concern even after this raise and notes active consideration of significant cost cuts and potential bankruptcy protection if additional capital or partnerships are not secured. The company also faces Nasdaq delisting risk due to its share price remaining below the $1.00 minimum bid requirement, with an extension to regain compliance by April 27, 2026.
Sangamo Therapeutics reported detailed Phase 1/2 STAAR data for its Fabry disease gene therapy isaralgagene civaparvovec (ST-920) and a clear U.S. regulatory path. The FDA agreed that this single Phase 1/2 study can serve as the primary basis for Accelerated Approval, using mean annualized eGFR slope at 52 weeks as the key endpoint.
The study treated 33 adults with a one-time infusion and showed a generally well-tolerated safety profile, with no deaths, no thrombotic microangiopathy or complement activation, and mostly mild or moderate adverse events. All 18 patients who entered on enzyme replacement therapy were able to stop ERT after dosing, while enzyme activity, kidney function slopes, cardiac measures, quality of life, gastrointestinal symptoms, and Fabry disease severity scores remained stable or improved over follow-up, supporting the ongoing rolling BLA submission.
Sangamo Therapeutics, Inc. reported a preliminary estimate that its cash and cash equivalents were approximately $20.9 million as of December 31, 2025. This figure is unaudited, subject to change, and may be adjusted when the audited financial statements for 2025 are completed.
The company also disclosed a leadership change in its finance team. On February 2, 2026, the employment of Prathyusha Duraibabu, the principal financial officer, terminated. Effective February 3, 2026, Nikunj Jain, Vice President, Finance and Corporate Controller and principal accounting officer, was appointed Interim Chief Financial Officer and will serve as the principal financial officer without additional compensation.
Sangamo Therapeutics’ Principal Accounting Officer, Nikunj Jain, reported an automatic share withholding tied to restricted stock units. On January 22, 2026, 7,721 shares of common stock underlying a vested RSU tranche were surrendered back to Sangamo at $0.3985 per share to cover mandatory tax withholding under the company’s 2018 Equity Incentive Plan. This is treated as a disposition for reporting purposes but is not a discretionary open-market trade.
After this tax withholding event, Jain beneficially owned 242,996 shares, including RSUs from grants dated February 24, 2023, January 22, 2024, and February 25, 2025 that vest over time, as well as 5,000 shares acquired under the 2020 Employee Stock Purchase Plan.
Sangamo Therapeutics’ principal financial officer, Prathyusha Duraibabu, reported an automatic share withholding tied to restricted stock vesting. On January 22, 2026, 36,676 shares of common stock were surrendered to the company at $0.3985 per share to cover mandatory tax withholding on a vested restricted stock unit (RSU) grant. This is treated as a disposition to the issuer for reporting purposes but was not a discretionary sale in the open market.
After this tax withholding event, the officer beneficially owned 660,042 shares of common stock, including shares underlying multiple RSU grants that vest over time, subject to continued service under the company’s 2018 Equity Incentive Plan.
Sangamo Therapeutics executive Scott B. Willoughby, SVP, Chief Legal Officer and Secretary, reported a routine share disposition tied to equity compensation. On January 22, 2026, 36,676 shares of common stock were surrendered to Sangamo solely for mandatory tax withholding on a restricted stock unit (RSU) vesting, using the company’s closing stock price of $0.3985 per share. This is treated as a disposition to the issuer for reporting purposes but was not a discretionary trade in the open market.
After this transaction, Willoughby beneficially owned 665,410 shares of common stock. This amount includes 52,387 shares from the January 22, 2026 vesting of a January 22, 2024 RSU grant, 4,008 RSU shares scheduled to vest quarterly through February 24, 2026, and 120,000 RSU shares from a February 25, 2025 grant that will vest beginning February 25, 2026, subject to continued service and potential acceleration under the company’s 2018 Equity Incentive Plan.
Sangamo Therapeutics president and CEO Sandy Macrae reported a Form 4 transaction involving company common stock. On January 22, 2026, 102,950 shares were automatically surrendered at a price of $0.3985 per share to cover mandatory tax withholding tied to the vesting of restricted stock units under Sangamo’s 2018 Equity Incentive Plan. This is treated as a disposition to the company for reporting purposes but was not a discretionary open-market trade. After this tax-withholding event, Macrae beneficially owned 1,946,584 shares of Sangamo common stock, including multiple RSU grants that continue to vest over time, subject to ongoing service conditions.
Sangamo Therapeutics reported an insider equity transaction by Davis Gregory D, its Head of Research & Technology. On January 22, 2026, a portion of his restricted stock units vested and 7,721 shares of common stock were surrendered solely to cover mandatory tax withholding at a price of $0.3985 per share under the company’s 2018 Equity Incentive Plan.
After this tax withholding event, he beneficially owns 191,062 shares of common stock, including vested and unvested RSUs and 5,000 shares previously acquired through the 2020 Employee Stock Purchase Plan. The filing notes this is a required tax withholding transaction and not a discretionary open-market sale.
Sangamo Therapeutics, Inc. reported an insider equity transaction by SVP and Chief Development Officer Nathalie Dubois-Stringfellow. On January 22, 2026, 36,676 shares of common stock were surrendered at $0.3985 per share to cover mandatory tax withholding on a vesting restricted stock unit (RSU) grant, under the company’s 2018 Equity Incentive Plan. This is treated as a disposition to the company for reporting purposes but was not a discretionary open-market trade.
Following this tax withholding event, Dubois-Stringfellow beneficially owned 693,128 shares of Sangamo common stock. This total includes previously vested RSUs, unvested RSUs that will vest over time if service continues, and shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Sangamo Therapeutics officer and Principal Accounting Officer reported an automatic share disposition related to restricted stock units. On November 24, 2025, 578 shares of common stock were surrendered to the company solely to cover mandatory tax withholding on a vesting RSU grant, using the issuer's closing stock price of $0.4166 per share. This is treated as a disposition to the issuer for reporting purposes but is not a discretionary open-market trade.
After this transaction, the reporting person beneficially owned 245,717 shares, including shares from multiple RSU grants that vest over time through February 24, 2026 and beyond, subject to continued service and the terms of the company’s 2018 Equity Incentive Plan.